Turkey-US Collaborative Program for Affordable Medical Technologies (R01)
This Funding Opportunity Announcement (FOA) invites applications from research partnerships formed between scientists from U.S. and Turkey to accelerate the development of appropriate affordable diagnostic and therapeutic technologies, which address medical needs in low-middle resource settings. Appropriate medical technologies are those that are useable, cost effective, sustainable, and effective in meeting a significant clinical need in a lower-middle resource setting in different world regions.
The collaborations should be aimed at developing medical technologies that can significantly impact underserved populations within the United States and/or Turkey and potentially populations in Low and Middle Income Countries (LMICs), particularly in Africa, the Middle East and Eastern Europe. This Funding Opportunity Announcement (FOA) encourages efforts towards developing or reengineering existing medical technologies to make them affordable and efficient so that they will have a significant impact on cancer The program places special emphasis on the need for medical technologies that will have translational potential. Funding may be requested to enhance, adopt, validate, and translate so that the technologies can accomplish cancer risk assessment, screening, detection, diagnosis, treatment or monitor treatment related outcomes. The proposed technology/device should be cost effective and widely applicable in LMICs, and offer capabilities comparable to those available in clinical settings of higher income countries.
The collaboration must involve at least one U.S. investigator from an eligible U.S. institution and at least one Turkish collaborator affiliated with an eligible Turkish institution. An eligible Turkish institution is either a non-profit or a recognized academic institution as determined by The Scientific and Technological Research Council of Turkey TUBITAK. The applications must involve integrated research projects that are enriched by the inclusion of scientific expertise of both U.S. and Turkish institutions.
- R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
- AIDS Due Dates: Jan. 7, May 7, Sep. 7
PAR-15-276 Expiration Date January 8, 2018
Budgets are limited to $100,000 in direct costs in any single year.
The maximum project period is 2 years.